Ebola virus disease: Biology, diagnosis, treatment and prevention of epidemics

被引：0
作者：
Kumar S. [1 ,2 ]
Kumari R. [2 ]
Pandey R. [3 ]
Sharma V. [1 ,2 ]
机构：
[1] SKA Institution for Research, Education and Development (SKAIRED), 4/11 Sarv Priya Vihar, New Delhi
[2] National Institute of Plant Genome Research (NIPGR), Aruna Asaf Ali Marg, New Delhi
[3] Division of Natural Products Chemisrty, CSIR-Indian Institute of Chemical Technology, Uppal Road, Tarnaka Uppal Road, Hyderabad
来源：
Proceedings of the Indian National Science Academy | 2017年 / 83卷 / 01期
关键词：
Anti-ebola therapeutics/vaccines; Cytokine storm; Ebola genetics; Ebolavirus disease; Filovirus; Repurposed drugs;
D O I：
10.16943/ptinsa/2017/41286
中图分类号：
学科分类号：
摘要：
Ebola virus disease (EVD) is a highly lethal contagious disease caused by the negative RNA strand Ebola virus. Reservoired in wild forest animals of Africa, Ebola virus infects humans that come in direct contact of diseased animals and outbreaks of EVD result from person to person spread of infection. A recent EVD outbreak in West Africa has killed several thousand persons. Since Ebola infection will persist in animals, EVD epidemics are expected to continue to occur in future. Infected travellers from Africa can initiate/import outbreaks in countries of other continents. This review describes the properties of the Ebola virus and EVD, the ongoing attempts to develop diagnostics, vaccines and medicines for prevention and cure of EVD and the supportive care that saves some EVD patients. Also discussed are measures that can stop and prevent EVD outbreaks. Need for inclusion of EVD in the education, research, drug and medical equipment manufacturing programmes, of the densly populated countries such as India, is emphasised. © Printed in India.
引用
收藏
页码：103 / 149
页数：46
相关论文
共 169 条
  • [1] Acha P.N., Szyfres B., In PAn American health organization, Zoonoses and Communicable Diseases Common to Man and Animals, pp. 142-145, (2003)
  • [2] Adu-Gyamfi E., Soni S.P., Xue Y., Digman M.A., Gratton E., Stahelin R.V., The Ebola virus matrix protein penetrates into the plasma membrane: A key step in viral protein 40 (VP40) oligomerization and viral egress, J Biol Chem, 288, pp. 5779-5789, (2013)
  • [3] Adu-Gyamfi E., Soni S.P., Jee C.S., Digman M.A., Gratton E., Stahelin R.V., A loop region in the N-Terminal domain of Ebola virus VP40 is important in viral assembly, budding, and egress, Viruses, 6, pp. 3837-3854, (2014)
  • [4] Agnandji S.T., Et al., Phase I trials of rVSV Ebola vaccine in Africa and Europe, New Engl J Med, 374, pp. 1647-1660, (2016)
  • [5] Ahrberg C.D., Manz A., Newzil P., Palm-sized device for point-of-care Ebola detection, Analyt Chem, 88, pp. 4803-4807, (2016)
  • [6] Alfson K.J., Worwa G., Carrion R., Griffiths A., Determination of the spontaneous mutation frequency of Ebola virus and exploitation of this therapeutically, J Virol, pp. 02701-02715, (2016)
  • [7] Allela L., Bourry O., Pouillot R., Delicat A., Yaba P., Kumulungui B., Rouquet P., Gonzalez J.P., Leroy E.M., Ebola virus antibody prevalence in dogs and human risk, Emerg Infect Dis, 11, pp. 385-390, (2005)
  • [8] Alvarez C.P., Lasala F., Carrillo J., Muniz O., Corbi A.L., Delgado R., C-Type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans, J Virol, 76, pp. 6841-6844, (2014)
  • [9] Ansari A.A., Clinical features and pathobiology of Ebolavirus infection, J Autoimmun, 55, pp. 1-9, (2014)
  • [10] Ascenzi P., Bocedi A., Heptonstall J., Capobianchi M.R., Di C.A., Mastrangelo E., Bolognesi M., Ippolito G., Ebolavirus and Marburgvirus: Insight the filoviridae family, Mol Aspects Med, 29, pp. 151-185, (2008)
12345678910